Wed 11-12-19 - Earnings date for Aleafia - Thanks Diogenes for finding this news. It's going to be exciting to see "the-profit" they announced on 9-24-19 that will be there. I hope it's not just an accounting trick or one-off, but a real EBITDA and GAAP Black profit.
GlobeNewswire About: ALEAF
Aleafia Health to Announce 2019 Third Quarter Financial Results
TORONTO, Oct. 23, 2019 (GLOBE NEWSWIRE) -- Aleafia Health Inc. (ALEAF) (“Aleafia Health” or the “Company”) will announce its 2019 Third Quarter Financial Results on November 12, 2019 prior to market open. The Company will also host its Third Quarter Results Call the same day at 8:30 a.m. EST. The call will be hosted by CEO Geoffrey Benic and CFO Benjamin Ferdinand.
CONFERENCE CALL & WEBCAST
Date: November 12, 2019 Time: 8:30 a.m. EST USA/Canada Toll-Free Participant Call-in: (866) 679-9046; Passcode: 7778885 International Toll-Free Participant Call-in: (409) 217-8323; Passcode: 7778885
WEBCAST LINK HERE
This conference call will be webcast live over the internet and can be accessed through the link provided. Audio of the call will be available to participants through both the conference call line and webcast; however, the presentation may only be viewed via the webcast. Participants who miss the live call can view a replay at any time via the link provided.
Aleafia Health is a leading, vertically integrated cannabis health and wellness company with four primary business units: Cannabis Cultivation & Products, Health & Wellness Clinics, Cannabis Education, and Consumer Experience with ecommerce, retail distribution and provincial supply agreements.
Aleafia Health owns three major cannabis product & cultivation facilities, two of which are licensed and operational including the first large-scale, operational outdoor cultivation facility in Canadian history. The Company produces a diverse portfolio of commercially proven, high-margin derivative products including oils, capsules and sprays. Aleafia Health operates the largest national network of medical cannabis clinics and education centres staffed by MDs, nurse practitioners and educators and has international operations in three continents.
Innovation is at the heart of Aleafia Health competitive advantage. The Company maintains a medical cannabis dataset with over 10 million data points to inform proprietary illness-specific product development and its highly differentiated education platform FoliEdge Academy. The Company is committed to creating sustainable shareholder value and has been named the 2019 top performing company of the year by the TSX Venture Exchange prior to graduation to the TSX.
Earnings clarity - Not Aleafia's problem. Mgmt & the BoD might be the smartest people in the cannabis industry. Not only do the have the lowest flower cost per gram, but they went ahead and build a multi-million dollar extraction facility that many bigger companies don't have yet. They will be cost efficient for a long time, and be able to produce white label products for others.
Pot Earnings Confound Analysts After the Sector’s Horrible Year Bloomberg
By: Kristine Owram Bloomberg October 25, 2019
This is the story of the day. Profits will be elusive until the first companies rightsize to demand, and Health Canada releases the distribution choke hold this new industry has to deal with.
Aleafia on the the other hand is already rightsized, and ready to post a profit with the lowest revenues in the cannabis industry.
(Bloomberg) -- During a year in which pot stocks have cratered, the outlook for earnings has become hazier than almost any other sector.
The average spread between the highest and lowest analyst estimate for full-year earnings per share is C$1.15 ($0.88) for the 10 largest cannabis stocks, wider than any other sector on the S&P/TSX Composite Index excluding financials, according to data compiled by Bloomberg.
For example, full-year adjusted EPS estimates for Canopy Growth Corp., the largest pot company by market value, range from a loss of C$5.47 to a loss of 44 cents. Cronos Group Inc.’s estimates range from a loss of C$1.40 to a profit of C$2.14.
By comparison, the average spread for consumer staples is 27 cents and the average spread for energy is 79 cents.
It’s an indication of how difficult it is to get a handle on the outlook for an emerging sector when there’s still plenty of uncertainty about what the future holds, said Greg Taylor, chief investment officer at Purpose Investments Inc. and manager of the Purpose Marijuana Opportunities Fund.
“A lot of these companies rushed out to become public and are really learning on the fly about how to do a lot of things, and one of those is how to handle expectations,” Taylor said. “When you’re an analyst it’s hard to have a ton of confidence in guidance, or you might not be getting any guidance at all.”
Hexo Stumble
That uncertainty has taken a toll on valuations. Pot stocks have lost more than half their value since their highs earlier this year, with the Horizons Marijuana Life Sciences Index ETF down about 53% since March 19.
Hexo Corp., for example, recently cut its fiscal fourth-quarter revenue guidance to a range of C$14.5 million to C$16.5 million after previously saying it would double from the third-quarter level of C$13 million. It also withdrew its fiscal 2020 guidance for C$400 million in sales and announced Thursday it would cut about 200 of its 822 staff members.
Analysts who cover Hexo have steadily cut their average earnings per share outlook for the current year, from a loss of 7.6 cents in January to a loss of 21 cents today.
“This is a sector that’s relatively new and a lot of the analysts who have been bullish over the last year have been burned already,” Taylor said. “That’s why you’re getting a wider range -- you might get a few who are still newer to the names and want to take a risk, but most have been so disappointed with the recent performance that they’ve put lower expectations in their models.”
To contact the reporter on this story: Kristine Owram in Toronto at kowram@bloomberg.net
To contact the editors responsible for this story: Brad Olesen at bolesen3@bloomberg.net, ;Courtney Dentch at cdentch1@bloomberg.net, Jacqueline Thorpe
News 
Market Data 
Discover 
